- Active, not recruiting
NCT03290950: Phase 2 - A Study of Daratumumab in Patients With NDMM wKRd-D - Manhattan Trial
Updated: Sep 25, 2022
MANHATTAN TRIAL
NCT03290950: Phase 2 - A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Dara-KRd

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for patients.
Carfilzomib (Kyprolis)
Lenalidomide (Revlimid)
Dexamethasone (Decadron)
Daratumumab (Darzalex)
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborator